Antibody-Drug Conjugates

doi:10.7536/PC130650

KMS > 免疫化学研究所

	Antibody-Drug Conjugates
	Cao Gang 1; Huang Zuogang 1; Cheng Jiefei 2; Jiang Biao1,3,4
	2014-03
发表期刊	PROGRESS IN CHEMISTRY (IF:1.0[JCR-2023],1.0[5-Year])
ISSN	1005-281X
卷号	26 期号:2-3 页码:467-477
发表状态	已发表
DOI	10.7536/PC130650
摘要	Over 35 monoclonal antibody drugs have been marketed since the approval of first monoclonal antibody drug in 1986, making the antibody drug development one of the most exciting fields. Antibody-drug conjugate (ADC), which combines a monoclonal antibody (mAb) with a cytotoxic (drug) molecule through a linker and thereby the name, is a new class of highly potent biopharmaceutical drugs designed as a targeted therapy. ADC takes advantage of the high binding specificity of mAbs and superior efficacy of cytotoxic molecules, while avoiding the dose-limiting toxicity of cytotoxic molecules. The first ADC, Mylotarg, was approved in 2000, which was late withdrawn by the manufacture due to the lack of appropriate stability of the linker. So far, there are two approved ADCs in the market for cancer therapy and over twenty ADCs in various stages of clinical trials. Creating a successful antibody drug conjugate requires careful selection of the drug, antibody and linker. Linker has a great influence on a conjugate' s biological characteristics, such as stability in circulation and drug release at the target site. ADCs have been proven to be effective weapons against cancers and will certainly become useful therapeutics against other diseases.
关键词	antibody-drug conjugate (ADC) linker mAbs cytotoxic molecules
收录类别	SCI
语种	中文
资助项目	National Natural Science Foundation of China[20832007]
WOS研究方向	Chemistry
WOS类目	Chemistry, Multidisciplinary
WOS记录号	WOS:000333506800024
出版者	CHINESE ACAD SCIENCES
WOS关键词	ACUTE MYELOID-LEUKEMIA ; CANCER-THERAPY ; CALICHEAMICIN CONJUGATE ; MONOCLONAL-ANTIBODIES ; TARGETED TREATMENT ; LINKER STABILITY ; CYTOTOXIC DRUGS ; IN-VIVO ; IMMUNOCONJUGATE ; CELLS
原始文献类型	Review
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/2417
专题	免疫化学研究所免疫化学研究所_特聘教授组_抗体化学实验室
通讯作者	Cheng Jiefei
作者单位	1.Chinese Acad Sci, Shanghai Adv Res Inst, Shanghai 201210, Peoples R China 2.Otsuka Shanghai Res Inst, Shanghai 201203, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai 200032, Peoples R China 4.ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 200031, Peoples R China
推荐引用方式 GB/T 7714	Cao Gang,Huang Zuogang,Cheng Jiefei,et al. Antibody-Drug Conjugates[J]. PROGRESS IN CHEMISTRY,2014,26(2-3):467-477.
APA	Cao Gang,Huang Zuogang,Cheng Jiefei,&Jiang Biao.(2014).Antibody-Drug Conjugates.PROGRESS IN CHEMISTRY,26(2-3),467-477.
MLA	Cao Gang,et al."Antibody-Drug Conjugates".PROGRESS IN CHEMISTRY 26.2-3(2014):467-477.